Profil
Shana Kay Phares served as the President & Chief Executive Officer at Blanchette Rockefeller Neurosciences Institute from 2010 to 2016.
She then worked as a Director at Neurotrope, Inc. from 2016 to 2020.
Prior to her career in neuroscience, she earned an undergraduate degree from Harvard University and an MBA from West Virginia University.
Anciens postes connus de Shana Kay Phares
| Sociétés | Poste | Fin |
|---|---|---|
| NEUROTROPE, INC. | Directeur/Membre du Conseil | 25/02/2020 |
Blanchette Rockefeller Neurosciences Institute
 Blanchette Rockefeller Neurosciences Institute BiotechnologyHealth Technology Blanchette Rockefeller Neurosciences Institute provides health care solutions. The company offers to facilitate molecular signaling, which controls the functions that record our conscience experience. The company is headquartered in Morgantown, WV. | Directeur Général | 01/01/2016 |
Formation de Shana Kay Phares
| West Virginia University | Masters Business Admin |
| Harvard University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Blanchette Rockefeller Neurosciences Institute
Blanchette Rockefeller Neurosciences Institute BiotechnologyHealth Technology Blanchette Rockefeller Neurosciences Institute provides health care solutions. The company offers to facilitate molecular signaling, which controls the functions that record our conscience experience. The company is headquartered in Morgantown, WV. | Health Technology |
Neurotrope, Inc.
 Neurotrope, Inc. Pharmaceuticals: MajorHealth Technology Neurotrope, Inc. is a biopharmaceutical company, which engages in the pre-clinical and clinical development of its product candidates. The company focuses on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease. It also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X and Niemann-Pick Type C. The company was founded on January 11, 2011 and is headquartered in New York, NY. | Health Technology |